RAB6B

Across TCGA pan-cancer cohorts, RAB6B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAB6B data layer compared with 29 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RAB6B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RAB6B expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where RAB6B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.948	0.763	.006	28	view →
CCRCC	OS	Median	III,IV	0.538	0.856	.013	11	view →
PDAC	DFS	Median	III,IV	0.535	0.165	.011	9	view →
GBM	DFS	Quartile	All	0.296	0.586	.025	4	view →
LSCC	DFS	Median	II,III,IV	0.451	0.877	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAB6B–HNSC (OS)

Open the HNSC breakdown →